Over the past 12 months, $CYTK has been discussed by 2 distinct FinTwit voices, with 19 total mentions. Adam Feuerstein (@adamfeuerstein) dominated coverage with 18 mentions, while Jon Erlichman (@jonerlichman) contributed 1 mention. The first mention in the archive appeared on August 30, 2025, and discussion continued through May 5, 2026, with biotech analysis being the primary focus category.

The most recent conversation centered on Cytokinetics' Myqorzo and its ACACIA study results in nHCM (non-obstructive hypertrophic cardiomyopathy). On May 5, 2026, Feuerstein reported that both co-primary endpoints achieved statistical significance. He also detailed safety data showing that 10% of patients experienced reduced left ventricle ejection fraction, with two cases progressing to heart failure that were managed with diuretics without requiring additional intervention.